BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61:S14-S25. [PMID: 25443342 DOI: 10.1016/j.jhep.2014.06.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 145] [Article Influence: 24.3] [Reference Citation Analysis]
Number Citing Articles
1 Carloni G, Fioretti D, Rinaldi M, Ponzetto A. Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas. Crit Rev Oncol Hematol 2019;138:156-71. [PMID: 31092372 DOI: 10.1016/j.critrevonc.2019.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver Int 2018;38:1906-10. [PMID: 30022590 DOI: 10.1111/liv.13932] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
3 Aregay A, Owusu Sekyere S, Deterding K, Port K, Dietz J, Berkowski C, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. J Hepatol 2019;71:889-99. [PMID: 31295532 DOI: 10.1016/j.jhep.2019.06.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
4 Stalder H, Bachofen C, Schweizer M, Zanoni R, Sauerländer D, Peterhans E. Traces of history conserved over 600 years in the geographic distribution of genetic variants of an RNA virus: Bovine viral diarrhea virus in Switzerland. PLoS One 2018;13:e0207604. [PMID: 30517140 DOI: 10.1371/journal.pone.0207604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Thoens C, Heinold A, Lindemann M, Horn PA, Chang DI, Scherbaum N, Timm J, Heinemann FM. A Single-Nucleotide Polymorphism Upstream of the HLA-C Locus Is Associated With an Anti-Hepatitis C Virus-Seronegative State in a High-Risk Exposed Cohort. J Infect Dis 2018;218:2016-9. [PMID: 30102364 DOI: 10.1093/infdis/jiy492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Quarleri JF, Oubiña JR. Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence. Ann Hepatol 2016;15:17-26. [PMID: 26626636 DOI: 10.5604/16652681.1184193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
8 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 79] [Cited by in F6Publishing: 56] [Article Influence: 19.8] [Reference Citation Analysis]
9 Xie C, Li SY, Fang JH, Zhu Y, Yang JE. Functional long non-coding RNAs in hepatocellular carcinoma. Cancer Lett 2021;500:281-91. [PMID: 33129957 DOI: 10.1016/j.canlet.2020.10.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hiramatsu K, Matsuda H, Nemoto T, Nosaka T, Saito Y, Naito T, Takahashi K, Ofuji K, Ohtani M, Suto H, Yasuda T, Hida Y, Kimura H, Soya Y, Nakamoto Y. Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C. J Med Virol 2017;89:1574-83. [PMID: 28332201 DOI: 10.1002/jmv.24814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015;35:1923-33. [PMID: 25939775 DOI: 10.1111/liv.12861] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
12 Leber B, Balázs I, Horvath A, Posch A, Streit A, Spindelböck W, Feldbacher N, Stiegler P, Stauber RE, Rechberger GN, Kollroser M, Sattler W, Nusshold C, Stadlbauer V. Direct acting antiviral therapy rescues neutrophil dysfunction and reduces hemolysis in hepatitis C infection. Transl Res 2021;232:103-14. [PMID: 33352296 DOI: 10.1016/j.trsl.2020.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ma S, Liu A, Hu X, Feng Q, Zhang Y, Li N, Peng J, Sheng Z. Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron. Biochem Pharmacol 2021;186:114436. [PMID: 33539815 DOI: 10.1016/j.bcp.2021.114436] [Reference Citation Analysis]
14 Echebli N, Tchitchek N, Dupuy S, Bruel T, Peireira Bittencourt Passaes C, Bosquet N, Le Grand R, Bourgeois C, Favier B, Cheynier R, Lambotte O, Vaslin B. Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection. PLoS One 2018;13:e0190334. [PMID: 29324751 DOI: 10.1371/journal.pone.0190334] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Liu HM, Ma LL, Cao B, Lin JZ, Han L, Li CY, Xu RC, Zhang DK. Progress in research into the role of abnormal glycosylation modification in tumor immunity. Immunol Lett 2021;229:8-17. [PMID: 33186635 DOI: 10.1016/j.imlet.2020.11.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Stadler D, Kächele M, Jones AN, Hess J, Urban C, Schneider J, Xia Y, Oswald A, Nebioglu F, Bester R, Lasitschka F, Ringelhan M, Ko C, Chou WM, Geerlof A, van de Klundert MA, Wettengel JM, Schirmacher P, Heikenwälder M, Schreiner S, Bartenschlager R, Pichlmair A, Sattler M, Unger K, Protzer U. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep 2021;22:e49568. [PMID: 33969602 DOI: 10.15252/embr.201949568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial 2019;32:127-34. [PMID: 30569604 DOI: 10.1111/sdi.12761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
18 Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J. Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. J Infect Dis 2019;220:1209-18. [PMID: 31165162 DOI: 10.1093/infdis/jiz274] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
19 Chun K, Afshar M, Audish D, Kabigting F, Paik A, Gallo R, Hata T. Hepatitis C may enhance key amplifiers of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:672-678. [PMID: 27184185 DOI: 10.1111/jdv.13578] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
20 Holmes JA, Carlton-Smith C, Kim AY, Dumas EO, Brown J, Gustafson JL, Lauer GM, Silva ST, Robidoux M, Kvistad D, Alatrakchi N, Tonnerre P, Cohen DE, Zhang H, Shulman NS, Chung RT. Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. J Viral Hepat 2019;26:362-72. [PMID: 30450781 DOI: 10.1111/jvh.13041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
21 de Brito WB, Queiroz MAF, da Silva Graça Amoras E, Lima SS, da Silva Conde SRS, dos Santos EJM, Cayres-vallinoto IMV, Ishak R, Vallinoto ACR. The TGFB1 -509C/T polymorphism and elevated TGF-β1 levels are associated with chronic hepatitis C and cirrhosis. Immunobiology 2020;225:152002. [DOI: 10.1016/j.imbio.2020.152002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Strunz B, Hengst J, Deterding K, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK. Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. Nat Commun 2018;9:2275. [PMID: 29891939 DOI: 10.1038/s41467-018-04685-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
23 Bertol BC, Dias FC, Debortoli G, Souto BM, Mendonça PB, Araújo RC, Santana RC, Ramalho LNZ, Castelli EC, Martinelli ALC, Mendes-Junior CT, Carosella ED, Donadi EA, Moreau P. HLA-G liver expression and HLA-G extended haplotypes are associated with chronic hepatitis C in HIV-negative and HIV-coinfected patients. Clin Immunol 2020;217:108482. [PMID: 32470543 DOI: 10.1016/j.clim.2020.108482] [Reference Citation Analysis]
24 Lucas KD, Wheeler C, McLendon P, Leistikow BN, Mohle-Boetani JC. Outbreak of Legionnaires' disease associated with cooling towers at a California state prison, 2015. Epidemiol Infect 2018;146:297-302. [PMID: 29386076 DOI: 10.1017/S0950268818000110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Szereday L, Meggyes M, Berki T, Miseta A, Farkas N, Gervain J, Par A, Par G. Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C. Clin Exp Med 2020;20:219-30. [PMID: 32108916 DOI: 10.1007/s10238-020-00618-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Lai F, Chen Q. Humanized Mouse Models for the Study of Infection and Pathogenesis of Human Viruses. Viruses 2018;10:E643. [PMID: 30453598 DOI: 10.3390/v10110643] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
27 Han W, Li J, Zhou H, Qian J, Tong Z, Wang W, Zhong J, Xue T, Chen Q, Yao Y, Shao S. Identification of the association of CD28+ CD244+ Tc17/IFN-γ cells with chronic hepatitis C virus infection. J Med Virol 2020. [PMID: 32568409 DOI: 10.1002/jmv.26205] [Reference Citation Analysis]
28 Peng C, Wang H, Zhang WJ, Jie SH, Tong QX, Lu MJ, Yang DL. Inhibitory effect of miR-125b on hepatitis C virus core protein-induced TLR2/MyD88 signaling in THP-1 cells. World J Gastroenterol 2016;22:4354-61. [PMID: 27158204 DOI: 10.3748/wjg.v22.i17.4354] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Li Z, Liu Q. Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF-2. FEBS Lett 2018;592:2323-33. [PMID: 29885262 DOI: 10.1002/1873-3468.13152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, Cammà C, Cabibi D, Di Marco V, Fracanzani AL, Badiali S, Nobili V, Fargion S, Grimaudo S, Craxì A. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease: Petta, Valenti, et al. Hepatology 2017;66:1885-93. [DOI: 10.1002/hep.29395] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
31 Ran M, Chen H, Liang B, Liao W, Jiang J, Huang J, Ning C, Zang N, Zhou B, Liao Y, Liu H, Qin F, Yang Q, Li J, Ho W, Liang H, Ye L. Alcohol-induced autophagy via upregulation of PIASy promotes HCV replication in human hepatoma cells. Cell Death Dis 2018;9:898. [PMID: 30185779 DOI: 10.1038/s41419-018-0845-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
32 Yan J, Zhang Y, Su Y, Tian L, Qin P, Xu X, Zhou Y. microRNA-125a targets MAVS and TRAF6 to modulate interferon signaling and promote HCV infection. Virus Res 2021;296:198336. [PMID: 33577860 DOI: 10.1016/j.virusres.2021.198336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hirano J, Yoshio S, Sakai Y, Songling L, Suzuki T, Itoh Y, Zhang H, Chen DV, Haga S, Oomori H, Kodama T, Maeda Y, Ono Y, Takahashi Y, Standley DM, Yamamoto M, Moriishi K, Moriya K, Kanto T, Takehara T, Koike K, Matsuura Y, Okamoto T. Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. Proc Natl Acad Sci U S A 2021;118:e2026184118. [PMID: 34035171 DOI: 10.1073/pnas.2026184118] [Reference Citation Analysis]
34 Badshah Y, Arshad N, Khan M, Jannat A, Hayat H. Association of Interleukin-4 (-590 C/T) and Interleukin-6 (-174 G/C) Polymorphism in Pathogenesis and Prognosis of Hepatitis C Virus Infection. Journal of Interferon & Cytokine Research 2018;38:559-65. [DOI: 10.1089/jir.2018.0081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Roca Suarez AA, Testoni B, Baumert TF, Lupberger J. Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease. Front Immunol 2020;11:624034. [PMID: 33613561 DOI: 10.3389/fimmu.2020.624034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Grassi G, Di Caprio G, Fimia GM, Ippolito G, Tripodi M, Alonzi T. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol. 2016;22:1953-1965. [PMID: 26877603 DOI: 10.3748/wjg.v22.i6.1953] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
37 Coto-Llerena M, Lepore M, Spagnuolo J, Di Blasi D, Calabrese D, Suslov A, Bantug G, Duong FH, Terracciano LM, De Libero G, Heim MH. Interferon lambda 4 can directly activate human CD19+ B cells and CD8+ T cells. Life Sci Alliance 2021;4:e201900612. [PMID: 33158978 DOI: 10.26508/lsa.201900612] [Reference Citation Analysis]
38 Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem 2017;398:817-37. [PMID: 28455951 DOI: 10.1515/hsz-2017-0118] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
39 de Souza Pires-Neto O, da Silva Graça Amoras E, Queiroz MAF, Demachki S, da Silva Conde SR, Ishak R, Cayres-Vallinoto IMV, Vallinoto ACR. Hepatic TLR4, MBL and CRP gene expression levels are associated with chronic hepatitis C. Infect Genet Evol 2020;80:104200. [PMID: 31962161 DOI: 10.1016/j.meegid.2020.104200] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Vallianou I, Dafou D, Vassilaki N, Mavromara P, Hadzopoulou-Cladaras M. Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha, a key regulator of hepatocellular carcinoma. Int J Biochem Cell Biol 2016;78:315-26. [PMID: 27477312 DOI: 10.1016/j.biocel.2016.07.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
41 Wieland D, Thimme R. Vaccine-induced hepatitis C virus-specific CD8+ T cells do not always help. Hepatology 2016;63:1411-4. [PMID: 26662626 DOI: 10.1002/hep.28388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Harak C, Meyrath M, Romero-Brey I, Schenk C, Gondeau C, Schult P, Esser-Nobis K, Saeed M, Neddermann P, Schnitzler P, Gotthardt D, Perez-Del-Pulgar S, Neumann-Haefelin C, Thimme R, Meuleman P, Vondran FW, De Francesco R, Rice CM, Bartenschlager R, Lohmann V. Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. Nat Microbiol 2016;2:16247. [PMID: 27991882 DOI: 10.1038/nmicrobiol.2016.247] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
43 Mele D, Mantovani S, Oliviero B, Grossi G, Ludovisi S, Mondelli MU, Varchetta S. Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. Antiviral Res 2017;137:108-11. [PMID: 27876497 DOI: 10.1016/j.antiviral.2016.11.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
44 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
45 Cho H, Kang H, Lee HH, Kim CW. Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. Int J Mol Sci 2017;18:E1517. [PMID: 28703774 DOI: 10.3390/ijms18071517] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
46 Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. Infect Genet Evol 2018;66:376-91. [PMID: 28811194 DOI: 10.1016/j.meegid.2017.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
47 Refaat B, Ashshi AM, El-Shemi AG, Azhar E. Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy. Mediators Inflamm 2015;2015:287640. [PMID: 25969625 DOI: 10.1155/2015/287640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
48 Hengst J, Strunz B, Deterding K, Ljunggren H, Leeansyah E, Manns MP, Cornberg M, Sandberg JK, Wedemeyer H, Björkström NK. Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapy. Eur J Immunol 2016;46:2204-10. [DOI: 10.1002/eji.201646447] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 18.8] [Reference Citation Analysis]
49 Hofmann M, Thimme R. Kill, control, or escape: Immune responses in viral hepatitis. Clin Liver Dis (Hoboken) 2016;8:79-82. [PMID: 31041069 DOI: 10.1002/cld.576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
50 Cuypers L, Li G, Neumann-Haefelin C, Piampongsant S, Libin P, Van Laethem K, Vandamme AM, Theys K. Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evol 2016;2:vew024. [PMID: 27774307 DOI: 10.1093/ve/vew024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
51 Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99-105. [PMID: 27741441 DOI: 10.1016/j.coviro.2016.09.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
52 Baumert TF, Schuster C, Cosset FL, Dubuisson J, Hofmann M, Tautz N, Zeisel MB, Thimme R. Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses. J Hepatol 2016;64:968-73. [PMID: 26780288 DOI: 10.1016/j.jhep.2015.12.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
53 García-Álvarez M, Berenguer J, Jiménez-Sousa MA, Pineda-Tenor D, Aldámiz-Echevarria T, Tejerina F, Diez C, Vázquez-Morón S, Resino S. Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study. Sci Rep 2017;7:41516. [PMID: 28139728 DOI: 10.1038/srep41516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
54 Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M, Wedemeyer H. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. J Infect Dis. 2016;214:1965-1974. [PMID: 27683821 DOI: 10.1093/infdis/jiw457] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 15.2] [Reference Citation Analysis]
55 Stevenson TJ, Barbour Y, McMahon BJ, Townshend-Bulson L, Hewitt AM, Espera HGF, Homan C, Holck P, Luna SV, Knall C, Simons BC. Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection. Open Forum Infect Dis 2019;6:ofz223. [PMID: 31249845 DOI: 10.1093/ofid/ofz223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
56 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Li SY, Zhang ZN, Jiang YJ, Fu YJ, Shang H. Transcriptional insights into the CD8+ T cell response in mono-HIV and HCV infection. J Transl Med 2020;18:96. [PMID: 32093694 DOI: 10.1186/s12967-020-02252-9] [Reference Citation Analysis]
58 Vidal-Castiñeira JR, López-Vázquez A, Diaz-Bulnes P, Díaz-Coto S, Márquez-Kisinousky L, Martínez-Borra J, Navascues CA, Sanz-Cameno P, de la Vega J, Astudillo A, Rodríguez M, López-Larrea C. Genetic contribution of endoplasmic reticulum aminopeptidase 1 polymorphisms to liver fibrosis progression in patients with HCV infection. J Mol Med (Berl) 2020;98:1245-54. [PMID: 32647953 DOI: 10.1007/s00109-020-01948-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Álvaro-Meca A, Jiménez-Sousa MA, Boyer A, Medrano J, Reulen H, Kneib T, Resino S. Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit. BMC Infect Dis 2016;16:122. [PMID: 26979964 DOI: 10.1186/s12879-016-1448-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
60 Wedemeyer H, Khera T, Strunz B, Björkström NK. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? Front Immunol 2020;11:571166. [PMID: 33133084 DOI: 10.3389/fimmu.2020.571166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
61 Afsharzadeh F, Bokharaei-Salim F, Esghaei M, Monavari SH, Merat S, Poustchi H, Haj-Sheykholeslami A, Keyvani H. The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection. Hepat Mon 2016;16:e42388. [PMID: 28123444 DOI: 10.5812/hepatmon.42388] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
62 Pascut D, Hoang M, Nguyen NNQ, Pratama MY, Tiribelli C. HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers (Basel) 2021;13:2485. [PMID: 34069740 DOI: 10.3390/cancers13102485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Pfaender S, Walter S, Todt D, Behrendt P, Doerrbecker J, Wölk B, Engelmann M, Gravemann U, Seltsam A, Steinmann J, Burbelo PD, Klawonn F, Feige K, Pietschmann T, Cavalleri JV, Steinmann E. Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. J Gen Virol 2015;96:2636-42. [PMID: 26041875 DOI: 10.1099/vir.0.000208] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
64 Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Antiviral Res 2017;148:53-64. [PMID: 29074219 DOI: 10.1016/j.antiviral.2017.10.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
65 Jiménez-Sousa MA, Berenguer J, Rallón N, Pineda-Tenor D, Aldamiz-Echevarria T, Soriano V, García-Álvarez M, Vazquez-Morón S, Restrepo C, Carrero A, Benito JM, Resino S. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. Liver Int 2016;36:1258-66. [PMID: 26836972 DOI: 10.1111/liv.13079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
66 Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol 2018;24:5297-311. [PMID: 30598575 DOI: 10.3748/wjg.v24.i47.5297] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
67 Sidorkiewicz M, Grek M, Jozwiak B, Krol A, Piekarska A. The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression. Eur J Clin Microbiol Infect Dis 2017;36:697-702. [PMID: 27888401 DOI: 10.1007/s10096-016-2851-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
68 Komolmit P, Charoensuk K, Thanapirom K, Suksawatamnuay S, Thaimai P, Chirathaworn C, Poovorawan Y. Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial. PLoS One 2017;12:e0174608. [PMID: 28376103 DOI: 10.1371/journal.pone.0174608] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
69 Cai C, Koch B, Morikawa K, Suda G, Sakamoto N, Rueschenbaum S, Akhras S, Dietz J, Hildt E, Zeuzem S, Welsch C, Lange CM. Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. Front Immunol 2018;9:723. [PMID: 29706960 DOI: 10.3389/fimmu.2018.00723] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
70 Davidson S, Maini MK, Wack A. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interferon Cytokine Res. 2015;35:252-264. [PMID: 25714109 DOI: 10.1089/jir.2014.0227] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 17.2] [Reference Citation Analysis]
71 Jiménez-Sousa MA, Berenguer J, García-Álvarez M, Gutierrez-Rivas M, Aldámiz-Echevarria T, Tejerina F, Diez C, Vázquez-Morón S, Resino S. Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients. AIDS 2016;30:465-70. [PMID: 26760234 DOI: 10.1097/QAD.0000000000000908] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
72 Hofmann M, Thimme R. MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection. Eur J Immunol 2016;46:2099-102. [PMID: 27479232 DOI: 10.1002/eji.201646581] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
73 Jiménez-Sousa MA, Berenguer J, Fernández-Rodríguez A, Medrano LM, Aldámiz-Echevarria T, Pérez-Latorre L, Díez C, Martín-Vicente M, Gutiérrez-Rivas M, Martínez I, Resino S. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study. Infect Genet Evol 2019;67:112-20. [PMID: 30336268 DOI: 10.1016/j.meegid.2018.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
74 Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep 2016;6:22995. [PMID: 26965318 DOI: 10.1038/srep22995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
75 Gao QJ, Xie JX, Wang LM, Zhou Q, Zhang SY. Interaction effects among IFN-γ+874, IL-2-330, IL-10-1082, IL-10-592 and IL-4-589 polymorphisms on the clinical progression of subjects infected with hepatitis B virus and/or hepatitis C virus: a retrospective nested case-control study. BMJ Open 2017;7:e013279. [PMID: 28838891 DOI: 10.1136/bmjopen-2016-013279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
76 Lunemann S, Schöbel A, Kah J, Fittje P, Hölzemer A, Langeneckert AE, Hess LU, Poch T, Martrus G, Garcia-Beltran WF, Körner C, Ziegler AE, Richert L, Oldhafer KJ, Schulze Zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M. Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture. Gastroenterology 2018;155:1366-1371.e3. [PMID: 30031767 DOI: 10.1053/j.gastro.2018.07.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
77 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 150] [Article Influence: 47.3] [Reference Citation Analysis]
78 Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 14.6] [Reference Citation Analysis]
79 Boldanova T, Suslov A, Heim MH, Necsulea A. Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver. EMBO Mol Med 2017;9:816-34. [PMID: 28360091 DOI: 10.15252/emmm.201607006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
80 Thöns C, Senff T, Hydes TJ, Manser AR, Heinemann FM, Heinold A, Heilmann M, Kim AY, Uhrberg M, Scherbaum N, Lauer GM, Khakoo SI, Timm J. HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs. J Hepatol 2017;67:462-70. [PMID: 28412292 DOI: 10.1016/j.jhep.2017.03.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
81 Boldeanu MV, Siloşi I, Bărbulescu AL, Sandu RE, Geormăneanu C, Pădureanu V, Popescu-Drigă MV, Poenariu IS, Siloşi CA, Ungureanu AM, Dijmărescu AL, Boldeanu L. Host immune response in chronic hepatitis C infection: involvement of cytokines and inflammasomes. Rom J Morphol Embryol 2020;61:33-43. [PMID: 32747893 DOI: 10.47162/RJME.61.1.04] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Obaid A, Naz A, Ikram A, Awan FM, Raza A, Ahmad J, Ali A. Model of the adaptive immune response system against HCV infection reveals potential immunomodulatory agents for combination therapy. Sci Rep 2018;8:8874. [PMID: 29891859 DOI: 10.1038/s41598-018-27163-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
83 Lee KC, Cheng YT, Lin CY, Kuo CJ, Chien RN, Yeh CT, Chang ML. Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13-year prospective cohort study. Eur J Clin Invest 2020;50:e13189. [PMID: 31782138 DOI: 10.1111/eci.13189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
85 Yang CM, Yoon JC, Park JH, Lee JM. Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3. PLoS One 2017;12:e0175793. [PMID: 28410411 DOI: 10.1371/journal.pone.0175793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
86 Peña-Asensio J, Sanz-de-Villalobos E, Miquel J, Larrubia JR. Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history. World J Hepatol 2020;12:754-65. [PMID: 33200014 DOI: 10.4254/wjh.v12.i10.754] [Reference Citation Analysis]
87 Mazouz S, Boisvert M, Shoukry NH, Lamarre D. Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. CanLivJ 2018;1:78-105. [DOI: 10.3138/canlivj.1.2.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Dominguez-Molina B, Ferrando-Martinez S, Tarancon-Diez L, Hernandez-Quero J, Genebat M, Vidal F, Muñoz-Fernandez MA, Leal M, Koup R, Ruiz-Mateos E. Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers. Front Immunol 2018;9:2897. [PMID: 30619267 DOI: 10.3389/fimmu.2018.02897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
89 Serti E, Park H, Keane M, O’Keefe AC, Rivera E, Liang TJ, Ghany M, Rehrmann B. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. Gut. 2016; Epub ahead of print. [PMID: 26733671 DOI: 10.1136/gutjnl-2015-310033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
90 Lohmann V. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Med Microbiol Immunol 2019;208:3-24. [PMID: 30298360 DOI: 10.1007/s00430-018-0566-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
91 Refolo G, Ciccosanti F, Di Rienzo M, Basulto Perdomo A, Romani M, Alonzi T, Tripodi M, Ippolito G, Piacentini M, Fimia GM. Negative Regulation of Mitochondrial Antiviral Signaling Protein-Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus Infection. Hepatology 2019;69:34-50. [PMID: 30070380 DOI: 10.1002/hep.30149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
92 Wandrer F, Falk CS, John K, Skawran B, Manns MP, Schulze-Osthoff K, Bantel H. Interferon-Mediated Cytokine Induction Determines Sustained Virus Control in Chronic Hepatitis C Virus Infection. J Infect Dis 2016;213:746-54. [PMID: 26503984 DOI: 10.1093/infdis/jiv505] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
93 Heim MH, Bochud PY, George J. Host - hepatitis C viral interactions: The role of genetics. J Hepatol 2016;65:S22-32. [PMID: 27641986 DOI: 10.1016/j.jhep.2016.07.037] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
94 Osuch S, Metzner KJ, Caraballo Cortés K. Reversal of T Cell Exhaustion in Chronic HCV Infection. Viruses 2020;12:E799. [PMID: 32722372 DOI: 10.3390/v12080799] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Hartlage AS, Walker CM, Kapoor A. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus. J Virol 2020;94:e00035-20. [PMID: 32102885 DOI: 10.1128/JVI.00035-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
96 Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, Port K, Manns MP, Vogel A, Cornberg M, Wedemeyer H. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther. 2018;47:516-525. [PMID: 29205405 DOI: 10.1111/apt.14427] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
97 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 31.0] [Reference Citation Analysis]
98 Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol 2021;74:220-9. [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
99 Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A. Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis. J Hepatol 2018;68:421-30. [PMID: 29100993 DOI: 10.1016/j.jhep.2017.10.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
100 Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res 2018;248:53-62. [PMID: 29477639 DOI: 10.1016/j.virusres.2018.02.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 27.3] [Reference Citation Analysis]
101 Faure-Dupuy S, Delphin M, Aillot L, Dimier L, Lebossé F, Fresquet J, Parent R, Matter MS, Rivoire M, Bendriss-Vermare N, Salvetti A, Heide D, Flores L, Klumpp K, Lam A, Zoulim F, Heikenwälder M, Durantel D, Lucifora J. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J Hepatol 2019;71:1086-98. [PMID: 31349000 DOI: 10.1016/j.jhep.2019.06.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
102 Scagnolari C, Antonelli G. Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome. Cytokine Growth Factor Rev 2018;40:19-31. [PMID: 29576284 DOI: 10.1016/j.cytogfr.2018.03.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
103 Lu MY, Huang CI, Hsieh MY, Hsieh TJ, Hsi E, Tsai PC, Tsai YS, Lin CC, Hsieh MH, Liang PC, Lin YH, Hou NJ, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML. Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. Oncotarget 2016;7:61325-35. [PMID: 27542257 DOI: 10.18632/oncotarget.11348] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
104 Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses. 2018;10. [PMID: 30274202 DOI: 10.3390/v10100531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
105 Amaddeo G, Nguyen CT, Maillé P, Mulé S, Luciani A, Machou C, Rodrigues A, Regnault H, Mallat A, Laurent A, Lafdil F, Hézode C, Pawlotsky JM, Calderaro J. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. Liver Int 2020;40:74-82. [PMID: 31444947 DOI: 10.1111/liv.14226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
106 Groepper C, Rufinatscha K, Schröder N, Stindt S, Ehlting C, Albrecht U, Bock HH, Bartenschlager R, Häussinger D, Bode JG. HCV modifies EGF signalling and upregulates production of CXCR2 ligands: Role in inflammation and antiviral immune response. J Hepatol 2018;69:594-602. [PMID: 29705238 DOI: 10.1016/j.jhep.2018.04.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
107 Drori Y, Jacob-Hirsch J, Pando R, Glatman-Freedman A, Friedman N, Mendelson E, Mandelboim M. Influenza A Virus Inhibits RSV Infection via a Two-Wave Expression of IFIT Proteins. Viruses 2020;12:E1171. [PMID: 33081322 DOI: 10.3390/v12101171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
108 Fellay J, Pedergnana V. Exploring the interactions between the human and viral genomes. Hum Genet 2020;139:777-81. [PMID: 31729546 DOI: 10.1007/s00439-019-02089-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
109 Toro DM, Ramasawmy R, Silva Neto PV, Pereira GL, Sarmento PS, Dray HLSN, Sousa KS, Affonso JS, Silva JA, Garcia NP, Barbieri MV, Victória FS, Donadi EA, Costa AG, Ogusku MM, Sadahiro A, Tarragô AM, Malheiro A. Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil. PLoS One 2021;16:e0253470. [PMID: 34161370 DOI: 10.1371/journal.pone.0253470] [Reference Citation Analysis]
110 Nel I, Lucar O, Petitdemange C, Béziat V, Lapalus M, Bédossa P, Debré P, Asselah T, Marcellin P, Vieillard V. Accumulation of Intrahepatic TNF-α-Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection. Medicine (Baltimore) 2016;95:e3678. [PMID: 27175704 DOI: 10.1097/MD.0000000000003678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
111 Martini H, Citro A, Martire C, D'Ettorre G, Labbadia G, Accapezzato D, Piconese S, De Marzio P, Cavallari EN, Calvo L, Rizzo F, Severa M, Coccia EM, Grazi GL, Di Filippo S, Sidney J, Vullo V, Sette A, Barnaba V. Apoptotic Epitope-Specific CD8+ T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection. J Infect Dis 2016;213:674-83. [PMID: 26386427 DOI: 10.1093/infdis/jiv460] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
112 Burchill MA, Salomon MP, Golden-Mason L, Wieland A, Maretti-Mira AC, Gale M Jr, Rosen HR. Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes. PLoS Pathog 2021;17:e1009799. [PMID: 34370798 DOI: 10.1371/journal.ppat.1009799] [Reference Citation Analysis]
113 Rai KR, Shrestha P, Yang B, Chen Y, Liu S, Maarouf M, Chen JL. Acute Infection of Viral Pathogens and Their Innate Immune Escape. Front Microbiol 2021;12:672026. [PMID: 34239508 DOI: 10.3389/fmicb.2021.672026] [Reference Citation Analysis]
114 Medrano LM, Rallón N, Berenguer J, Jiménez-Sousa MA, Soriano V, Aldámiz-Echevarria T, Fernández-Rodríguez A, García M, Tejerina F, Martínez I, Benito JM, Resino S. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients. J Transl Med 2016;14:257. [PMID: 27590274 DOI: 10.1186/s12967-016-1005-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
115 Qin L, Zhou YC, Wu HJ, Zhuo Y, Wang YP, Si CY, Qin YM. Notch Signaling Modulates the Balance of Regulatory T Cells and T Helper 17 Cells in Patients with Chronic Hepatitis C. DNA Cell Biol 2017;36:311-20. [PMID: 28157396 DOI: 10.1089/dna.2016.3609] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
116 Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF. Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection. Hepatology 2019;70:1506-20. [PMID: 31062385 DOI: 10.1002/hep.30699] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
117 Balasiddaiah A, Davanian H, Aleman S, Pasetto A, Frelin L, Sällberg M, Lohmann V, Koh S, Bertoletti A, Chen M. Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties. J Virol 2017;91:e00010-17. [PMID: 28228595 DOI: 10.1128/JVI.00010-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
118 Merritt E, Londoño MC, Childs K, Whitehouse G, Kodela E, Sánchez-Fueyo A, Martínez-Llordella M. On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation. Am J Transplant 2021;21:247-57. [PMID: 32524678 DOI: 10.1111/ajt.16134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
119 Zuo C, Sheng X, Ma M, Xia M, Ouyang L. ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Oncotarget 2016;7:74393-409. [PMID: 27626310 DOI: 10.18632/oncotarget.11911] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
120 Abdelwahab SF. Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important? Infect Agent Cancer 2016;11:23. [PMID: 27186234 DOI: 10.1186/s13027-016-0070-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
121 Perpiñán E, Pérez-Del-Pulgar S, Londoño MC, Mariño Z, Lens S, Leonel T, Bartres C, García-López M, Rodriguez-Tajes S, Forns X, Koutsoudakis G. Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8+ T cells after direct-acting antiviral therapies. J Viral Hepat 2020;27:1408-18. [PMID: 32812325 DOI: 10.1111/jvh.13370] [Reference Citation Analysis]
122 Singh S, Vedi S, Samrat SK, Li W, Kumar R, Agrawal B. Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines. PLoS One 2016;11:e0146404. [PMID: 26751211 DOI: 10.1371/journal.pone.0146404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
123 Ray RB, Ray R. Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship. Hepatology. 2019;69:889-900. [PMID: 30102776 DOI: 10.1002/hep.30214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
124 Hu P, Wilhelm J, Gerresheim GK, Shalamova LA, Niepmann M. Lnc-ITM2C-1 and GPR55 Are Proviral Host Factors for Hepatitis C Virus. Viruses 2019;11:E549. [PMID: 31200545 DOI: 10.3390/v11060549] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
125 Gal-tanamy M. Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running. Gastroenterology 2019;157:300-2. [DOI: 10.1053/j.gastro.2019.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Lutckii A, Strunz B, Zhirkov A, Filipovich O, Rukoiatkina E, Gusev D, Lobzin Y, Fischler B, Aleman S, Sällberg M, Björkström NK. Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus. Gut 2020;69:2203-13. [PMID: 32341018 DOI: 10.1136/gutjnl-2019-320269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Tomer S, Chawla YK, Duseja A, Arora SK. Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection. World J Gastroenterol 2016;22:5173-82. [PMID: 27298560 DOI: 10.3748/wjg.v22.i22.5173] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
128 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
129 Urban C, Welsch H, Heine K, Wüst S, Haas DA, Dächert C, Pandey A, Pichlmair A, Binder M. Persistent Innate Immune Stimulation Results in IRF3-Mediated but Caspase-Independent Cytostasis. Viruses 2020;12:E635. [PMID: 32545331 DOI: 10.3390/v12060635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Lutterkort GL, Wranke A, Hengst J, Yurdaydin C, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Manns MP, Dienes HP, Falk C, Wedemeyer H, Heidrich B. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. J Viral Hepat 2018;25:1384-94. [DOI: 10.1111/jvh.12947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
131 Zheng H, Xu L, Liu Y, Li C, Zhang L, Wang T, Zhao D, Xu X, Zhang Y. MicroRNA-221-5p Inhibits Porcine Epidemic Diarrhea Virus Replication by Targeting Genomic Viral RNA and Activating the NF-κB Pathway. Int J Mol Sci 2018;19:E3381. [PMID: 30380612 DOI: 10.3390/ijms19113381] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
132 Møhlenberg M, Terczynska-dyla E, Thomsen KL, George J, Eslam M, Grønbæk H, Hartmann R. The role of IFN in the development of NAFLD and NASH. Cytokine 2019;124:154519. [DOI: 10.1016/j.cyto.2018.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
133 Gerresheim GK, Bathke J, Michel AM, Andreev DE, Shalamova LA, Rossbach O, Hu P, Glebe D, Fricke M, Marz M, Goesmann A, Kiniry SJ, Baranov PV, Shatsky IN, Niepmann M. Cellular Gene Expression during Hepatitis C Virus Replication as Revealed by Ribosome Profiling. Int J Mol Sci 2019;20:E1321. [PMID: 30875926 DOI: 10.3390/ijms20061321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
134 Gerresheim GK, Hess CS, Shalamova LA, Fricke M, Marz M, Andreev DE, Shatsky IN, Niepmann M. Ribosome Pausing at Inefficient Codons at the End of the Replicase Coding Region Is Important for Hepatitis C Virus Genome Replication. Int J Mol Sci 2020;21:E6955. [PMID: 32971876 DOI: 10.3390/ijms21186955] [Reference Citation Analysis]
135 Gerresheim GK, Roeb E, Michel AM, Niepmann M. Hepatitis C Virus Downregulates Core Subunits of Oxidative Phosphorylation, Reminiscent of the Warburg Effect in Cancer Cells. Cells 2019;8:E1410. [PMID: 31717433 DOI: 10.3390/cells8111410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
136 Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Höner Zu Siederdissen C, Deterding K, Lehmann P, Cloherty G, Reinhardt B, Pawlotsky JM, Manns MP, Zeuzem S, Cornberg M, Wedemeyer H, Sarrazin C. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol 2016;65:473-82. [PMID: 27085252 DOI: 10.1016/j.jhep.2016.04.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 10.6] [Reference Citation Analysis]
137 Singh P, J FPD. A Biomolecular Network Driven Proteinic Interaction in HCV Clearance. Cell Biochem Biophys 2018;76:161-72. [PMID: 29313175 DOI: 10.1007/s12013-017-0837-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Collister M, Ellison C, Li Q, Minuk GY, Rempel JD, Kung SK. The Influence of Hepatitis C Viral Loads on Natural Killer Cell Function. Gastroenterology Res 2019;12:8-15. [PMID: 30834029 DOI: 10.14740/gr1081w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
139 Dandri M, Bertoletti A, Lütgehetmann M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition. Semin Immunopathol 2021. [PMID: 34019142 DOI: 10.1007/s00281-021-00864-x] [Reference Citation Analysis]
140 Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Ishii A, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis. Medicine (Baltimore) 2016;95:e3194. [PMID: 27015216 DOI: 10.1097/MD.0000000000003194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
141 Niepmann M, Gerresheim GK. Hepatitis C Virus Translation Regulation. Int J Mol Sci. 2020;21. [PMID: 32230899 DOI: 10.3390/ijms21072328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
142 Hartlage AS, Dravid P, Walker CM, Kapoor A. Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats. PLoS Pathog 2021;17:e1009391. [PMID: 33735321 DOI: 10.1371/journal.ppat.1009391] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017;32:1754-1762. [PMID: 28230928 DOI: 10.1111/jgh.13771] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 16.0] [Reference Citation Analysis]
144 Anggakusuma, Romero-brey I, Berger C, Colpitts CC, Boldanova T, Engelmann M, Todt D, Perin PM, Behrendt P, Vondran FW, Xu S, Goffinet C, Schang LM, Heim MH, Bartenschlager R, Pietschmann T, Steinmann E. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology 2015;62:702-14. [DOI: 10.1002/hep.27913] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
145 Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, Baumert TF, Binder M, Urban S, Bartenschlager R. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology 2018;154:1791-1804.e22. [PMID: 29410097 DOI: 10.1053/j.gastro.2018.01.044] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 25.0] [Reference Citation Analysis]